期刊
CELL STEM CELL
卷 26, 期 5, 页码 617-619出版社
CELL PRESS
DOI: 10.1016/j.stem.2020.03.017
关键词
-
资金
- UK Multiple Sclerosis Society [MS50]
- Adelson Medical Research Foundation
- Intramural Research Program of NINDS/NIH
- European Research Council (ERC) [771411]
- Lister Institute
- Wellcome
- MRC [203151/Z/16/Z]
- MRC [G0701476, MC_PC_17230] Funding Source: UKRI
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003119] Funding Source: NIH RePORTER
- European Research Council (ERC) [771411] Funding Source: European Research Council (ERC)
Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
